Report center

医药生物行业中药板块2023三季报总结:季度波动不改景气,期待政策与业绩共振机会-20231105-华安证券

中药:乐观看待行业的政策与业绩共振机会 中药行情上半年得到充分演绎的情况下,即使当下有所回调,但行业性整体机会仍旧被市场看好,不过风格和方向需要重新把握。一季度的普涨行情一定程度上得益于放开后的终端需求拉动,带来业绩的普遍爆发,叠加22年的低基数得以表观业绩高增长。不过普遍的高增长难以为继,Q2\Q3虽然22年疫情有部分低基数效应,但增长速度放缓难以避免,到今年Q4和明年Q1更是有高基数效应,增速

No subject companies

Publishers

Suggested next hops

Ranked by edge type and evidence strength (max 5). Prefer these over scrolling the full lists.

  1. 1华安证券Published by or linked to this institution1
  2. 2Media & InternetSame industry · 1 related reports1
  3. 3FEDS Paper: The Standards Are in the Mail: Comparing Credit Card Supply IndicatorsSame industry · 1 related reports1
  4. 4Six Years of High-Frequency Phone Surveys: Lessons from Sub-Saharan AfricaSame industry · 1 related reports1
  5. 5Special Economic Zones in South Africa 2026: Policy ReviewSame industry · 1 related reports1

Other hot industries

Similar reports

← Back to knowledge graph